IHE-RO Technical Committee Face-to-Face August 1, 2018 2:00 – 5:30 CDT **Music City Center – Nashville TN Convention Center Rm 101D**

August 2-3, 2018 at 8:30-5:30 CDT August 4 8:30-12:00 CDT **Omni Hotel Level 2 Music Row 1**

Technical Committee Chairs: Scott Hadley, PhD, University of Michigan Chris Pauer, Sun Nuclear

IHERO Task Force Co-Chairs Bruce Curran, MS, ME, FAAPM, FACMP, FACR, AAPM / VCU Health Bridget Koontz, MD, Medical Director, RO Services, Duke Regional

Mission Statement: The American Association of Physicists in Medicine (AAPM) sponsors a multi-society 20 Task Force to undertake an initiative to promote the Integration of the Healthcare Enterprise (IHE) – Radiation Oncology (RO. Originally formed by the American Society for Radiation Oncology (ASTRO), it fosters seamless connectivity and integration of radiotherapy equipment and the patient health information systems. The Technical Committee of IHE-RO will undertake use cases defined by members from ASTRO. RSNA, American Association of Physicists in Medicine (AAPM), the American College of Radiology (ACR) and the Medical Imaging and Technology Alliance (MITA). In addition, members of the International community have also been invited to participate in IHE-RO. The IHE-RO Task Force, in close collaboration with radiotherapy product manufacturers, will develop appropriate integration profiles for radiation therapy and setup a demonstration of seamless communication among the full array of radiotherapy products.

30Attendees:

Name	Affiliation	Email	8/1	8/2	8/3	8/4
Chris Pauer	Sun Nuclear	chrispauer@sunnuclear.com	X	X	X	X
Scott Hadley	U. Mich.	swhadley@umich.edu	X	X	X	X
Walter Bosch	Wash. Univ.	wbosch@wustl.edu	X	X	X	X
Jill Moton	AAPM	Jill@aapm.org	X	X	X	X
Koua Yang	Philips	Koua.yang@philips.com	X	X	X	X
Rickard Holmberg	Raysearch Labs	Rickard.Holmberg@raysearchlabs.com	X	X	X	X
Stina Svensson	Raysearch Labs	Stina.svensson@raysearchlabscom	X	X		
Sven Siekmann	Brainlab	Sven.Siekmann@brainlab.com	Т	T	Т	T
Rishabh Kapoor	VCU/VHA	Rishabh.kapoor@va.gov	X	X	X	
Thomas Schwere	Varian	Thomas.Schwere@varian.com	X	X	X	X
Bob Pekarek	Accuray	bpekarek@accuray.com	X	X	X	X
Jim Percy	Elekta	Jim.percy@elekta.com	X	X	X	X
Habeeb Saleh	Univ. of Kansas	hsaleh@kumc.edu	X			

5

10

15

Bruce Rakes	Mevion	rbrakes@mevion.com	X	X	X	X
Johannes Stahl	United Imaging	Johannes.stahl@united-imaging.com	X	X	X	
Bruce Curran	AAPM / VCU	bhcurran@gmail.com	X	X	X	¥5
Tucker Meyers	EPIC	tucker@epic.com		X	X	
Dan Rutz	EPIC	drutz@epic.com		X	X	
Simon Andersson	Raysearch Labs	Simon.andersson@raysearchlabs.com		X		
Stephen Oyewale	Lawton, OK	Steve.oyewale@gmail.com	X			
Rok Stefanic	Cosylab		T			
Stuart Swerdloff	Elekta	Stuart.swerdloff@elekta.com	X			
Neelu Soni	Mercy Hospital, Springfield	SoniNeelu@yahoo.com	X			
Erli Chen	Chesline Medical Ctr.	echen@chesline.com	X			
Chuang Wang	MSKCC	wangci@mskcc.org	X			
Francis Beating	Versant		X			
Daniel Bridges	Gumma Univ., Japan			X		
Matthew Al- Ghazi	UC Irvine Health	malghazi@uci.edu		X	X	X

i. The TC has been waiting to publish Profiles in the TF pending successful testing in

i. HIS – content was discussed at TC meetings in Feb and Apr 2018
ii. Prescription in RO (RXRO) – Sup 147 is being prepared for Final Text

Connectathons.

iii. Deformable Registration

iv. Basic Quality Assurance Workflow (BQAW)

b. Advance Profiles:

40

45

50

55

60

65

70

75

80

90 95	v. Treatment Delivery – Record Content (TDRC) – to be prepared for Public Comment c. Test Tools for use for Connectathon d. Connectathon prep schedule i. Actor Testing Survey due to Walter ASAP ii. Test Tool results due to Walter by Aug 17 iii. Report Test Tool bugs and issues ASAP iv. Test datasets to be ready for download by Aug 31
100	 III. Topic 2: Profile Statuses a. Chris reviewed the status of IHE-RO Profiles in Technical Framework, Public Comment, In Process, Priorities b. ACTION 180801: Chris to update Profile table on ihe-ro.org wiki.
105	 IV. Topic 3: Level Set a. Updates on IHE-RO activities i. Planning 1. Results of two surveys of Use Cases have been prepared for TC review
110	 Mark Pepelea is to give an IHE webinar on the RO domain Oversight, Steering Committees Domain Coordination Committee – Change proposal to include DICOM content to Vol 3 Chapter 7 (drafted by Uli Busch) was reviewed. Approval of an updated version of this template is anticipated at the end of August 2018.
115	 b. AAPM i. RO-SSI meeting July 31, 2018 1. An updated version of the error message document was discussed. It includes a recommendation that error messages be logged for review by physicists. 2. Training and QA documents are in the pipeline.
120	 ii. JACMP to include a practical IT issues column. c. DICOM WG-7 Update – Walter updated the group on the WG-7 April 14-18, 2018 meeting d. AdvaMed and Standards Efforts – Jim Percy updated the group on RT3 Standard i. RT3-Machine Characteristics Standard 1. Standard document
125	2. Template for creating machine characterization3. XML Schema document Thursday August 2
130	 V. Topic 3.5: Review List of Proposed PC Use Cases a. The TC reviewed the "2018.07.19 IHE-RO Survey responses.xlsx" document from the PC. The list contains issues derived from AAPM and ASTRO surveys. It has been organized by Eric Vinson according to Issue Type, (e.g., "RO to HIS", "RO to RO",), Issue Level, b. ACTION 180802: Scott and Rishabh to review/triage this list during breakout session.
135	VI. Announcement that July 2018 TC minutes have been posted to http://wiki.ihe.net was made on 8/2/18.
140	VII. Topic 4: Deformable Registration a. The TC reviewed an early draft of the DRRO Profile. The draft defines Actors i. Def. Registrator ii. Def Registered Contourer iii. Def Registered Display

iv. Ref General Registered Dose Display v. Def Registered Compositing Plan vi. Def Registered Dose Compositor b. Test data can be derived from AAPM TG-132 report on validation of deformable registration. This report uses contour-based, landmark-based, and image similarity metrics to evaluate 145 registration. c. DIR task group to include i. Stina Svensson (RaySearch) - chair ii. Dan Thil (Elekta) iii. TBN (Varian) 150 iv. Rojano Kashani (UMich) v. Mark Pepelea (Philips) vi. TBN (MIM) vii. TBN (Mirada) viii. TBN (ImSimOA) 155 ix. Scott Hadley x. Walter Bosch d. Tasks/topics for the sub-group i. Survey usage of DSRO information object ii. Usage of contour guidance information. (Fiducials used to determine registration.) 160 iii. Metadata describing creation of DSRO? iv. Data transfer for support of validation. e. ACTION 180803: Group participants to forward contacts to Jill for survey of sub-group meeting times. (10am ET) 165 VIII. Topic 5: HIS Tucker Meyers reviewed a summary of message contents for communication between OIS and HIS (summary-of-progress-20180718.pdf) b. Discussion of the context for exchange of messages between OIS and HIS. Details were captured by Tucker Meyers. 170 i. What is the workflow context for treatment Intent? ii. The workflow may vary by institution. iii. The Intent may be updated (refined, expanded) based on workup. iv. Staging is included, but may not be determined when Intent is created. Staging may be represented both as free-text and using a structured representation (Code Scheme, 175 Code Value). v. Multiple site + diagnosis entries may be needed: use repeating groups c. ACTION 180804: Rishabh, Scott, Tucker to draft white paper outlining content of Physician Intent message to solicit feedback from physician community. i. Data model 180 ii. Data element descriptions iii. Lifecycle iv. May include coding options (in Appendix) v. Protocol (treatment per protocol guidelines? eligibility? consented? accrued?) 185 d. Other topics discussed i. Desired (latest) start date for therapy? Clinical use cases include coordination with concurrent chemo or bone marrow transplant for total body irradiation. Seek input from physicians.

ii. Dose units: use units of Gy for transfer.

iii. The content of Prescription is a superset of (and may be updated from) Intent.

e. The TC reviewed an example HL7v2 (chapter 12.3.2) message for Intent

i. Message Type may be *add*, *update*, or *delete*. Is a message type of *delete* needed? ii. Lifecycle identifier can be used to update patient status. (add to Pathway?) iii. Discussion of updates to Intent, creation of new Intent, creation of Prescription from 195 Intent. iv. Results message records the delivery of nominal dose for delivered fractions. This may involve delivery of multiple plans for one prescription. Reporting of therapy results is complex. Results are needed in the HIS by clinicians for *patient* management. Details of plan delivery can be maintained in the OIS. 200 Lunch break 12:40-1:40pm f. Scott Hadley presented Planning Directive (dynamic) documents – UMich templates in Aria. i. For each structure, these documents include priority, drawn by, image dataset, and 205 instructions for delineation. ii. Planning directive specifies treatment technique, including energy, bolus, IGRT parameters, etc. iii. Sim Directive is a separate document. iv. Workflow: Intent is created... Triggers Sim Directive... Plan is created... Triggers 210 Prescription... Prescription is approved. IX. Topic 8.5: TDW-II a. Thomas Schwere presented version 14 of the TDW-II Profile document. (version 13 was distributed 7/25/18.) i. DICOM content requirements for UPS has been moved to Chapter 7. 215 ii. Base UPS Scheduled Procedure Information is common for all RT UPS types. iii. Whenever possible, the existing UPS codes are to be used. iv. Treatment Delivery Procedure Step Input Information Sequence contains 1. RT Plan or RT Ion Plan 2. BDI 220 3. RT Beams Treatment Record (for continuation) v. Treatment Delivery Parameters (*=CP is needed to create codes for parameters – to be referred to DICOM WG-07) 1. Treatment Delivery Type 225 2. Plan Label* 3. Current Fraction Number* 4. Number of Fractions Planned* vi. Omitted Beam Task Sequence (300C,0111) is used to specify beams that are *not* to be delivered in the current session. The presence requirement for this attribute is changed to state that "...Zero or more items shall be present...". 230 vii. N-SET Progress Updates require notification of the current Beam Number. Procedure Step Progress Parameters Sequence (0074,1007) is to be used to encode the current Beam Number.

viii. The Procedure Step Progress refers to the "percent" completion of the scheduled

b. **DECISION**: The consensus of the TC is to keep the TDW-II Profile at Trial Implementation

Sequence indicates that no treatment has been delivered.

ix. Change to Table 3.65.2-2: Status of Tx Delivery – the presence of treatment record(s) in the Output Information Sequence indicates that a treatment has been (partially or completely) delivered. The absence of treatment records in the Output Information

beams for the plan to be delivered.

pending informal testing at the 2018 Connectation.

235

- X. Topic 11: Treatment Delivery Record Content
 - a. The TDRC Profile was edited in Aug 2017 to add RT Ion Plan attributes. These have since been removed, pending completion of TPPC-Ion content.
 - b. Chris reviewed version 0.8 (6/22/18) of the TDRC Profile draft.
 - c. The TC discussed the relationship among Specified and Delivered Primary and Secondary Meterset values. Confusion is possible between Specified Meterset (3008,0042) and Specified Primary Meterset (3008,0032) for continuation beams. The TC recommends to DICOM WG-07 to include a clarifying example in Section C.8.8.21.2.
 - d. The referenced DICOM Edition for this Profile should updated to 2018.
 - e. Dose reference information has been moved into the Control Point Sequence in RT Plan IOD. This may need to be updated in the TDRC DICOM content section.
 - f. Beam identifiers Referenced Beam Number (300C,0006) and Beam Name (300A,00C2) shall be present and match corresponding attributes, if present, in the RT Plan.
 - g. Table Top Position attributes (Type 2C) are R+.
 - h. Override Sequence (Type 3) is R+.

Friday August 3

XI. Topic 6: BRTO-II

60

- a. Sven Siekmann reviewed updates to the BRTO-II Profile document.
 - b. Missing entries in the Actor Options table (Table X.2-1) have been added.
 - c. The TC discussed requirements to handle unevenly spaced CT slices by Dosimetric Planner and Dose Displayer Actors.
 - d. **DECISION**: The RO-11 Resampled/Combined CT Series Storage Transaction was added as an Optional transaction for the Dosimetric Planner Actor.
 - e. This change is needed to maintain consistency among CT/RT Structure Set/RT Plan datasets. No change is needed for the Dose Displayer Actor.
 - f. **DECISION**: The Optionality of all transactions for the Archive Actor in BRTO-II was changed to R (Required).
 - g. Off-slice contours retrieved with the RO-7 (Standard) Structure Set Retrieval requires safe handling. (See Section 3.7.4)
 - h. ACTION 180805: Walter to communicate updates in BRTO-II Transaction Requirements to ICT
 - i. Revised document to be saved as revision 1.8.

XII. Topic 7: Prescription Profile (RXRO)

- a. Sven reviewed rev 0.11 of the RXRO draft with the TC.
- b. Sven has adapted descriptions of the three Use Cases.
- c. ACTION 180806: Bruce Curran to add a sentence to indicate that the Profile is intended to assist in compliance with legal requirements, however users must determine the adequacy for their jurisdiction.

285 XIII. Topic 8: TPPC

- a. Effective Wedge Angle value for a Motorized Wedge Beam
 - i. Required be stored by a Producer, may be consumed by a Consumer
 - ii. **DECISION**: Display of this value by Consumers will not be tested at the Connectathon.

XIV. Topic 5 Revisited: HIS

a. Reporting of Intent, Prescription, Results from OIS to HIS was discussed further. References to Plan (Label + UID) in Results Message were discussed. Plan identifiers may be used

260

245

250

255

265

270

275

280

forensically for comparison to the treatment record in the OIS, but are not needed by most 295 HIS users. For non-RO users, information should be minimal. b. The primary Use Case is for communication from Radiation Oncology to other medical disciplines responsible for patient care. Summary of RT for Survivorship Care Plan is a secondary Use Case. c. The concept of Site as a means to accumulate nominal doses was discussed. d. Dose information is organized by Site. For each Site, the Results message tracks the 300 following at each Session: i. Site ID ii. Fraction Number iii. Planned Fraction Count 305 iv. Nominal Fraction dose delivered v. Nominal Fraction dose planned vi. Cumulative nominal dose vii. (Total prescribed dose) viii. Delivery Completion Status e. This approach assumes a single OIS is the source of Results messages. Handling updates 310 from multiple OISs is an open issue. XV. Topic 9: Connectation Preparation – review of deadlines. 315 XVI. Topic 12.5: Use Cases suggested in this session XVII. Topic 10: Basic QA Workflow a. Chris reviewed the current revision (0.9) of the BQAW Profile draft with the TC. i. The Basic QA Workflow Profile defines five Actors: (1) Planning Data Provider, (2) Delivery Data Provider, (3) Planning Analysis Performer, (4) Delivery Analysis 320 Performer, and (5) Data Store. ii. The current draft uses DICOM Raw Data Storage to encapsulate proprietary data. The Raw Data IOD includes a description of content using a code sequence. iii. The TC discussed using the existence of a QA Results Report (with successful 325 evaluation results) to enable delivery of a plan. iv Transactions defined 1. Raw Data Storage 2. RT Image Storage 3. Content Assessment Results Storage 4. Encapsulated PDF Storage 330 5. KOS Document Storage 6. Store Tx Delivery Results 7. Single Series Image Retrieval 8. Spatial Reg-III Retrieval 9. Dosimetric Plan Storage 335 10. Dose Storage 11. Structure Set Storage v. Add RT Image Storage for measured and predicted fluence. b. The TC discussed other mechanisms for aggregating datasets for QA processing. 340 XVIII. Topic 11: Treatment Delivery – Record Content (continued) a. The TC reviewed changes incorporated in rev. 0.9 of the TDRC Profile based on work Aug 2.

b. Requirements for >> Specified Meterset (3008,0042) (Type2) and >> Delivered Meterset (3008,0044) (Type 1) were removed. The DICOM requirements control these attributes.

345 c. Table Top {Vertical, Longitudinal, Lateral} Position attributes are effectively 1C (shall not be NULL). d. Override Sequence shall be present if override was used. e. **DECISION**: The TDRC Profile (rev. 0.9, Aug 2) was voted to Public Comment. f. ACTION 180807: Chris to clean up TDRC text and distribute to IHE Domain Coordination 350 Committee for Public Comment by Aug 31. g. Amendment [8/4/18 at 9:00am] - The TC voted to include the following change in the Public Comment version of the TDRC Profile i. Add Current Fraction Number (3008,0022) and Treatment Delivery Type (300A,00CE) to TDRC with Requirement of "R+". 355 XIX. Topic 11.5: TPPC-ION (Treatment Planning – Ion Plan Content) a. Bruce Rakes reviewed draft (vers. 0.10) of the TPPC-ION Profile document b. The current draft addresses five beam types. c. Options: bolus, block, range compensator, and dynamic MLC d. The document does not currently address scattered beams or ocular beam lines. 360 e. There is no Archive Actor. f. For each Producer/Consumer pair there is a Storage and a Retrieval Transaction. g. The requirement for TPS to preserve Tolerance Tables in RT Ion Plan was flagged as an open issue. This requirement should be addressed in TDPC-ION. h. There may be some difficulty in defining Final Cumulative Meterset Weight for double-365 scattered ion beams Saturday August 4 370 XX. Test Tools a. The TC discussed the ICT Contract for support and development of Test Tools. XXI. Overflow topics from previous days. a. Presence requirements for DICOM attributes 375 i. DICOM Type 2 elements whose value is required should be indicated in Profiles as **R**+ or **R**+*. b. TDRC: include Current Fraction Number (3008,0022) and Treatment Delivery Type (300A,00CE) c. Discussion of the robustness of interoperability. Example: Identification of Treatment Delivery Device in QA Software 380 i. The TC discussed standard method(s) for referencing delivery devices. What happens when the Manufacturer Name changes? Is a registry of devices needed? Should the TDPC Profile call out attributes that are used to identify the delivery device? ii. Upgrading products is important. Interoperability between products is affected by 1. Software revisions 385 2. Editions of DICOM implemented in toolkit libraries 3. Configuration iii. Integration Profiles can expose dependencies and assumptions in the use of standards. iv. Effort and resources are needed to achieve and maintain interoperable exchange. v. ACTION 180808: Bruce and Scott to work with the Steering Committee on how to 390 better educate consumers on the capabilities and limitations of interoperability.

XXII. Topic 12: 4D Image Import

a. Scott reported on Profile proposal he is drafting for IHE-RAD domain on 4D Image Import.

395

400

405

b. ACTION 180809: Scott to submit IHE-RAD proposal for 4D imaging by Aug. 10, 2018. Chris will review.

XXIII. QA Workflow (continued)

- a. The group continued discussion of a proposal for an Integrated QA Checker Profile.
- b. The Data Provider Actor stores a set of treatment planning or treatment delivery artifacts after a trigger event occurs.

XXIV. QRRO – Query/Retrieve in Radiation Oncology

- a. Issues discussed include
 - i. Query keys
 - ii. Use cases are listed in clinical impact statement and "qrro-usecases_1.0.docx" document linked on ihe-ro.org wiki

XXV. Topic 13: Review Minutes

a. Draft minutes from TC meeting

b. Minutes from the July 2018 TC Teleconference were approved without objection.

XXVI. Topic 14: Review Action Items – the TC reviewed draft minutes and Action Items from this meeting.

415XXVII. Topic 15: Future Meetings / Next Agenda

- a. IHE-RO TC Meetings
 - i. Jan 14-18, 2019, Melbourne, FL
 - ii. April 2-5, 2019, after AAPM SCM, Orlando, FL
 - iii. Post-AAPM July 17-20, 2019, San Antonio, TX
 - iv. Fall Connectation Oct 7-12, 2019, Munich
 - v. Dec 9-13, 2019, Alexandria, VA
- b. IHE-RO TC Tcons
 - i. New time is third Thursdays 10:30am-12:00pm ET.
 - ii. No teleconferences scheduled in Aug and Sept. 2018.
- c. Other meetings of interest
 - i. DICOM WG-07
 - 1. October 24 (8:30am) October 27, 2018 (12pm) San Antonio, TX
 - 2. December 3 (8:30) December 7, 2018 (12:00) Melbourne, FL
 - 3. March 4-8, 2019 (tentative) Munich (Brainlab)
 - 4. July 29 Aug 2, 2019 Brainlab, Chicago (or MITA, Washington)
 - 5. Sept 23-29, 2019 *or* Sept 30 Oct 4, 2019 (tentatively in St. Louis)
 - 6. November 18-22, 2019 (tentative) Melbourne, FL (or MITA, Washington)

ii. PTCOG June 10, 2019

iii. AAPM Jul 14-18, 2019, San Antonio, TX

iv. ASTRO Sept. 15-18, 2019

v. RSNA Chicago, IL

XXVIII. Meeting Adjourned at 11:35am CT on 8/4/18.

430

420

425

435